Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams (Q24236653)

5

0 references

Mical Paul

1

0 references

Abigail Fraser

object named as

Abigail Fraser

4

0 references

Dafna Yahav

2

object named as

Dafna Yahav

0 references

Assaf Bivas

Cochrane Database of Systematic Reviews

3

object named as

Assaf Bivas

0 references

publication date

10 November 2010

0 references

published in

0 references

cites work

Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Beta-lactam regimens for the febrile neutropenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Cefepime versus ceftazidime as empirical therapy for fever in neutropenic patients with haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Cefepime vs. Meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Tre

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Single agent therapy for infections in cancer patients: a prospective randomized trial comparing three extended-spectrum cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Bacteremia in patients with febrile neutropenia after chemotherapy at a university medical center in Malaysia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Fungal infections in cancer patients: an international autopsy survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Meta-analysis of a possible signal of increased mortality associated with cefepime use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North Ame

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Ceftriaxone versus beta-lactams with antipseudomonal activity for empirical, combined antibiotic therapy in febrile neutropenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

21 January 2018

The new beta-lactamases.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: a view of the past decade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Bacteraemia in febrile neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Cefepime: an underrecognized cause of nonconvulsive status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Ceftazidime Monotherapy for Empiric Treatment of Febrile Neutropenic Patients: A Metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Cefepime-associated status epilepticus in an ICU patient with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Cefepime-induced nonconvulsive status epilepticus: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Factors associated with mortality in bacteremic patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Efficacy and safety of cefepime: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021

Sources and outcome of bloodstream infections in cancer patients: the role of central venous catheters

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021

Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021

Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021

Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021

Empiric monotherapy for febrile neutropenia--a randomized study comparing meropenem with ceftazidime

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021

Comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021

Evolution of antibiotic therapy for infection in neutropenic patients: studies at M. D. Anderson Hospital

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021

Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021

Safety profile of piperacillin/tazobactam in phase I and III clinical studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021

International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021

Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021

Comment on: empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021

A randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021

Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005197.PUB3

7 January 2021